Emtricitabine and Tenofovir Market Size, Share, Industry, Forecast and outlook (2023-2030)

The emtricitabine and tenofovir market is expected to grow at a 5% CAGR between 2023 and 2030, driven by factors like rising HIV prevalence, expanding PrEP programs, and increased access to generic versions of the drug.

Gilead Sciences is the leading player in the market, followed by companies like Cipla, Mylan Pharmaceuticals, Emcure Pharmaceuticals, Hetero Drugs, Sun Pharmaceutical Industries, Alkem Laboratories, Teva, Hengrui Medicine, SYSVAX, and Hisun Pharmaceutical.

North America is currently the largest market and is expected to remain dominant due to factors like high HIV prevalence and well-developed healthcare infrastructure.

The market faces challenges such as side effects associated with the drug, patent expiry of key drugs, and competition from other antiretroviral drugs.